Navigation Links
Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
Date:5/9/2011

our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010 and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

(Logo: http://photos.prnewswire.com/prnh/20110127/LA37605LOGO)

CONTACTS:

Investors: Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 bhertel@inovio.com

Media: Jeff Richardson, Richardson & Associates 805-491-8313 jeff@richardsonglobalpr.com


'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
2. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
3. Inovio Pharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference
4. Vanda Pharmaceuticals Reports First Quarter 2011 Results
5. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
6. Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
8. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
9. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
10. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
11. Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  ECC West Africa, ... Colorado with University College Hospital (UCH) Ibadan ... development project to finance, design, construct, and operate and ... Nigeria . Under the first of the ... scoping documents and funding applications. UCH Ibadan intends to ...
(Date:7/24/2014)... scientists are making progress in devising suitable means ... relies on quantum dotsa kind of artificial atom, ... new study demonstrates that changing the coupling of ... impulses can help better control them. This has ... quantum information units, which would produce faster quantum ...
(Date:7/24/2014)... Research and Markets has announced the addition ... report to their offering.  http://photos.prnewswire.com/prnh/20130307/600769 ... vitro growth of plant or animal cells for several ... Cell culture is a crucial step in tissue engineering ... consumables are necessary for the in vitro production of ...
(Date:7/24/2014)... SRI International has been awarded a new ... Allergy and Infectious Diseases (NIAID), part of the National ... therapies for HIV infection and AIDS. The contract supports ... and the complications and opportunistic infections associated with the ... of HIV. According to the World ...
Breaking Biology Technology:ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
... SAN DIEGO, July 24 Orexigen Therapeutics, Inc. ... fully exercised their overallotment option to purchase an additional 1,500,000 ... announced public offering that priced on July 23, 2009. ... at a public offering price of $7.50 per share, resulting ...
... , , , ... NES-ZIONA, Israel, July 24 PROLOR Biotech, Inc. (OTC Bulletin Board: PBTH), formerly ... private investors to sell up to $10 million of the company,s newly issued ... As part of the agreements, the company closed on the issuance of one ...
... , ... it used to be. ,Affordable biometric technology means you can,t get someone to buddy punch for you, ... from anywhere on the web, at anytime! , ... NSW (PRWEB) July 24, 2009 -- Technology is putting an end to the cat and mouse game ...
Cached Biology Technology:Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters 2PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group 2PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group 3PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group 4Time Clocks Technology Catches Up With Crooks 2Time Clocks Technology Catches Up With Crooks 3
(Date:7/24/2014)... average over a 35 year period in which the ... of humans on declining animal numbers. This decline matters ... spiders, crustaceans, slugs and worms bring to our day-to-day ... for nutrient cycling, water filtration and human health. , ... by UCL, Stanford and UCSB, focused on the demise ...
(Date:7/24/2014)... two factors that characterize sustainable university and college ... qualified physics teachers. Specifically, one or more faculty ... in combination with institutional motivation and commitment can ... Engineering and Math (STEM) teacher shortages are especially ... way for institutions seeking to increase the number ...
(Date:7/24/2014)... 3.5 billion years of evolutionary trial and error, is ... may be reaching a tipping point. , In a ... published in Science , an international team of ... is contributing to what appears to be the early ... , Since 1500, more than 320 terrestrial vertebrates have ...
Breaking Biology News(10 mins):Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Creating sustainable STEM teacher preparation programs 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3
... March 24, 2008) New BARACLUDE (entecavir) data ... resistance in nucleoside-nave patients through five years of ... patients analyzed, no additional patient developed resistance in ... treatment, the cumulative probability of developing mutations in ...
... HIV-positive African adults who become infected with Salmonella die ... diarrhea. Now, UC Davis School of Medicine scientists have ... findings also implicate a mechanism by which HIV evades ... have found the defect in the immune response that ...
... most often produced from biomass burning, cooking with solid ... the atmosphere three to four times greater than prevailing ... in the journal Nature Geoscience. Scripps Institution of ... and University of Iowa chemical engineer Greg Carmichael, said ...
Cached Biology News:BARACLUDE data show low resistance over 5 years in nucleoside-naive hepatitis B patients 2BARACLUDE data show low resistance over 5 years in nucleoside-naive hepatitis B patients 3UC Davis researchers discover how HIV turns food-poisoning into lethal infection 2UC Davis researchers discover how HIV turns food-poisoning into lethal infection 3Black carbon pollution emerges as major player in global warming 2Black carbon pollution emerges as major player in global warming 3
Mouse monoclonal antibody raised against a partial recombinant ZNF167. NCBI Entrez Gene ID = ZNF167...
...
...
... The Amplifluor UniPrimer-fluorescein is a hairpin ... transfer pair (fluorescein and non-fluorescent quencher) ... The UniPrimer is identical to ... Universal Detection System (S7901) and is ...
Biology Products: